Journal article

Walking Speed and Muscle Mass Estimated by the D3-Creatine Dilution Method Are Important Components of Sarcopenia Associated With Incident Mobility Disability in Older Men: A Classification and Regression Tree Analysis

Jesse Zanker, Sheena Patel, Terri Blackwell, Kate Duchowny, Sharon Brennan-Olsen, Steven R Cummings, William J Evans, Eric S Orwoll, David Scott, Sara Vogrin, Jane A Cauley, Gustavo Duque, Peggy M Cawthon

Journal of the American Medical Directors Association | ELSEVIER SCIENCE INC | Published : 2020

Abstract

Objectives It is unknown whether muscle mass measured by the D3-creatine dilution method is a superior predictor of incident mobility disability than traditional components of sarcopenia definitions (including grip strength, walking speed, appendicular lean mass). The objective of this study was to determine the relative importance of strength; physical performance; and lean, fat, and muscle mass in predicting incident mobility disability in older men. Design Longitudinal cohort study of participants in the Osteoporotic Fractures in Men (MrOS) study. Setting and Participants Muscle mass was assessed by D3-creatine dilution in 1098 men (aged 83.7 ± 3.7 years). Participants also completed anth..

View full abstract

Grants

Awarded by NIH Roadmap for Medical Research


Awarded by NIAMS


Awarded by National Health and Medical Research Council (NHMRC, of Australia) Career Development Fellowship


Awarded by National Health and Medical Research Council (NHMRC) Australia RDWright Biomedical Career Development Fellowship


Awarded by NHMRC Australia


Funding Acknowledgements

The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. Funding for the D3Cr muscle mass measure was provided by NIAMS (grant number R01 AR065268). GlaxoSmithKline provided in-kind support by providing the D3creatine dose and analysis of urine samples. J.Z. was supported to undertake this research by the Australian and New Zealand Society for Geriatric Medicine Travelling Scholarship, the Australian Institute for Musculoskeletal Science, and was also supported by an Australian Government Research Training Program Scholarship. S.B.-O. is supported by a National Health and Medical Research Council (NHMRC, of Australia) Career Development Fellowship (GNT1107510, 2016-2019) and a Medicine, Dentistry and Health Sciences (MDHS) Faculty Research Fellowship, University of Melbourne (2020). D.S. is supported by a National Health and Medical Research Council (NHMRC) Australia RDWright Biomedical Career Development Fellowship (GNT1123014) and a NHMRC Australia Investigator Grant (GNT1174886).